Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis.

Autor: Siddappa, Nagadenahalli B.^1,2, Hemashettar, Girish¹, Wong, Yin Ling¹, Lakhashe, Samir^1,2, Rasmussen, Robert A.^1,2, Watkins, Jennifer D.^1,2, Novembre, Francis J.^3,4, Villinger, François^3,5, Else, James G.^3,5, Montefiori, David C.⁶, Ruprecht, Ruth M.^1,2

Publikováno v: Journal of Medical Primatology. Apr2011, Vol. 40 Issue 2, p120-128. 9p.

In Vivo Validation of the Viral Barcoding of Simian Immunodeficiency Virus SIVmac239 and the Development of New Barcoded SIV and Subtype B and C Simian-Human Immunodeficiency Viruses.

Autor: Khanal S; AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, Maryland, USA., Fennessey CM; AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, Maryland, USA., O'Brien SP; AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, Maryland, USA., Thorpe A; AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, Maryland, USA., Reid C; AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, Maryland, USA., Immonen TT; AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, Maryland, USA., Smith R; AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, Maryland, USA., Bess JW Jr; AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, Maryland, USA., Swanstrom AE; AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, Maryland, USA., Del Prete GQ; AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, Maryland, USA., Davenport MP; Kirby Institute for Infection and Immunity, University of New South Wales, Sydney, Australia., Okoye AA; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Picker LJ; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA., Lifson JD; AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, Maryland, USA., Keele BF; AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, Maryland, USA keelebf@mail.nih.gov.

Publikováno v: Journal of virology [J Virol] 2019 Dec 12; Vol. 94 (1). Date of Electronic Publication: 2019 Dec 12 (Print Publication: 2019).

Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge

Autor: Sakeenah L. Hicks, Tiffany M. Styles, Vijayakumar Velu, Celia C. LaBranche, Pradeep B. J. Reddy, David C. Montefiori, Pamela A. Kozlowski, Cynthia A. Derdeyn, Sailaja Gangadhara, Rama Rao Amara

Publikováno v: Journal of virology. 93(20)

The RV144 human immunodeficiency virus type 1 (HIV-1) vaccine trial showed a strong association between anti-gp70 V1V2 scaffold (V1V2) and anti-V2 hot spot peptide (V2 HS) antibody responses and reduced risk of HIV infection. Accordingly, a primary g

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::048dabe2d6bbd91e6564634b919f2d9f
https://pubmed.ncbi.nlm.nih.gov/31341049